Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Relmada Therapeutics Inc 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 USA

www.relmada.com Employees: 17 P: 786-629-1376

Sector:

Medical

Description:

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 320,470
Enterprise Value, $K 316,610
Shares Outstanding, K 73,334
Annual Sales, $ 0 K
Annual Net Income, $ -79,980 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -10,090 K
EBIT, $ -57,850 K
EBITDA, $ -57,850 K
60-Month Beta 0.77
% of Insider Shareholders 20.70%
% of Institutional Shareholders 45.24%
Float, K 58,154
% Float 79.30%
Short Interest 981
Short Float 1.34%
Short Volume Ratio 0.47

Growth:

1-Year Return 870.90%
3-Year Return 32.83%
5-Year Return -87.66%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -22.69%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.30 on 11/13/25
Next Earnings Date 03/26/26
Earnings Per Share ttm -1.80
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 58.33%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 09/30/19

RLMD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -269.49%
Return-on-Assets % -205.22%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 16.94
Book Value/Share 0.29
Interest Coverage -1.12
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar